Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets
Date
2019-06
Authors
Pereira, Renato B.
Evdokimov, Nikolai M.
Lefranc, Florence
Valentao, Patricia
Kornienko, Alexander
Pereira, David M.
Andrade, Paula B.
Gomes, Nelson G. M
Journal Title
Journal ISSN
Volume Title
Publisher
Multidisciplinary Digital Publishing Institute
Abstract
The role of the marine environment in the development of anticancer drugs has been widely reviewed, particularly in recent years. However, the innovation in terms of clinical benefits has not been duly emphasized, although there are important breakthroughs associated with the use of marine-derived anticancer agents that have altered the current paradigm in chemotherapy. In addition, the discovery and development of marine drugs has been extremely rewarding with significant scientific gains, such as the discovery of new anticancer mechanisms of action as well as novel molecular targets. Approximately 50 years since the approval of cytarabine, the marine-derived anticancer pharmaceutical pipeline includes four approved drugs and eighteen agents in clinical trials, six of which are in late development. Thus, the dynamic pharmaceutical pipeline consisting of approved and developmental marine-derived anticancer agents offers new hopes and new tools in the treatment of patients afflicted with previously intractable types of cancer.
Description
Keywords
trabectedin, eribulin, brentuximab vedotin, plitidepsin, lurbinectedin, plinabulin, marizomib, plocabulin, antibody drug conjugates, cytarabine
Citation
Pereira, R. B., Evdokimov, N. M., Lefranc, F., Valentão, P., Kornienko, A., Pereira, D. M., Andrade, P. B., & Gomes, N. G. M. (2019). Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets. Marine Drugs, 17(6): 329.
Rights
Rights Holder
© 2019 The Authors.
Rights License
This work is licensed under a Creative Commons Attribution 4.0 International License.